pyridoxal phosphate and Diabetic Neuropathies

pyridoxal phosphate has been researched along with Diabetic Neuropathies in 8 studies

Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).
pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.

Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)

Research

Studies (8)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

(Exploratory) Change From Baseline in Levels of Hs-CRP at Week 24

(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory markers levels including hs-CRP (NCT00726713)
Timeframe: Analyte levels were taken at 0 (Baseline) and 24 weeks

(Exploratory) Change From Baseline in Levels of IL-6 and TNF-α, at Week 24

(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory marker levels, including IL-6 and TNF-α (NCT00726713)
Timeframe: Analyte levels were taken at 0 (Baseline) and 24 weeks

(Exploratory) Change From Baseline in Levels Potential Antioxidant (PAO) at Week 24

(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory markers levels including Potential Antioxidant (PAO) (NCT00726713)
Timeframe: Analyte levels were taken at 0 (Baseline) and 24 weeks

(Exploratory) Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Question Inventory at Week 24

The Hospital Anxiety and Depression Scale (HADS) consists of a 14-item questionnaire that provides a measurement of depression. Each item is rated on a 4-point scale, giving a maximum scores of 21 for the most severe depression. Depression was evaluated using the Hospital Anxiety and Depression Scale (HADS) question inventory at Baseline, and 24-week evaluation visits (NCT00726713)
Timeframe: HADS Scores scores were taken at 0 (Baseline) and 24 weeks

Change From Baseline in 10-point Visual Analog Scale(VAS) at Week 24

"To determine if Metanx® (compared to placebo) affects a subject's lower extremity pain level using a 10-point Visual Analog Scale at Baseline and 24-week evaluation visits.~The Visual Analog Scale (VAS) measures a patients sensation of pain. A 10-cm visual analog scale is used. A measurement on the 10 cm analog scale is used to quantify the level of pain indicated with 0 cm indicating no pain and 10 cm indicating the worst pain imaginable." (NCT00726713)
Timeframe: VAS scores were taken at 0 (Baseline) and 24 weeks

Change From Baseline in Neuropathy Disability Score (NDS)at Week 16 and 24

"This outcome was taken to determine if Metanx® (compared to placebo) has an effect on clinical examination as determined by the Neuropathy Disability Score (NDS)~The Neuropathy Disability Score (NDS) evaluates the severity of individual symptoms of neuropathy. A simple visual numeric distress scale is used that ranges from 0 to 10. The most favorable score is 0, which indicates an absence of symptoms. The most severe symptoms possible would be recorded as a score of 10." (NCT00726713)
Timeframe: NDS scores were taken at 0 (Baseline), 16, and 24 weeks

Change From Baseline in Neuropathy Total Symptom Score-6 (NTSS-6)

"This measure was taken to determine if Metanx® (compared to placebo) changes neuropathic symptoms as evaluated by the Neuropathy Total Symptom Score-6 (NTSS-6)~The Neuropathy Total Symptom Score-6 Scale (NTSS-6) is a validated scale that evaluates individual neuropathy sensory symptoms in patients with diabetes mellitus (DM) and diabetic peripheral neuropathy (DPN). This scale was a modified 6 item scale that consists of yes or no questions. Scores range between 0 and 21.96, a higher score indicates greater severity of symptoms. After adjusting for baseline measurements scores are reflected as negative numbers. Negative numbers indicate improvement in symptoms. ie. a change from baseline after 24 weeks of -2 would be a greater improvement than a change in baseline of -1 after 24 weeks." (NCT00726713)
Timeframe: NTSS-6 scores were taken at 0 (Baseline), 16, and 24 weeks

Change From Baseline in Plasma Marker Levels of Total Folate and Total Methyl Malonic Acid (MMA) at Week 16 and 24

To determine if Metanx® (compared to placebo) affects a change in subject's total folate and total methyl malonic acid (MMA) at week 16 and 24 (NCT00726713)
Timeframe: Change from Baseline in Plasma Marker Levels at 0 (Baseline), 16, and 24 weeks

Change From Baseline in SF-36 MCS and SF-36 PCS at Week 24

"To determine if Metanx® (compared to placebo) affects a subject's quality of life as determined by the SF-36 questionnaire~The Short Form- 36 Mental Component Summary (SF-36 MCS) and SF-36 Physical Component Summary (SF-36 PCS) both measure health related quality of life, the MCS quantifying mental health and the PCS quantifying physical function. They are both scored on 100 point scales with 0 representing the worst possible outcome and 100 representing the most optimal possible scoring" (NCT00726713)
Timeframe: SF-36 MCS and SF-36 PCS scores were measured at 0 (Baseline) and 24 weeks

Change From Baseline in Total Homocysteine at Week 16 and 24

To determine if Metanx® (compared to placebo) affects change in subjects total homocysteine levels (NCT00726713)
Timeframe: Change from Baseline in Plasma Marker Levels at 0 (Baseline), 16, and 24 weeks

Change From Baseline in Vibration Perception Threshold (VPT) at 24 Weeks

Vibration Perception Threshold (VPT) 25-45 volts at hallux on either leg as measured by VPT meter on the great toe of each foot. Mean VPT averaged across both toes. (NCT00726713)
Timeframe: VPT was measured a 0 (baseline), and 24 weeks

Trials

2 trials available for pyridoxal phosphate and Diabetic Neuropathies

Other Studies

6 other studies available for pyridoxal phosphate and Diabetic Neuropathies